Rezdiffra is exceeding Wall Street's expectations as the MASH market takes shape

When Novo Nordisk’s blockbuster weight loss drug Wegovy won approval in August 2025 to treat the fatty liver disease, some investors thought it would put competitive pressure on Madrigal Pharmaceuticals' liver-targeted therapy Rezdiffra. But it seems that Madrigal has managed to avoid that outcome.

Raccontata daendpoints.news